China Research and Intelligence (CRI) has emerged to provide high-level research and advisory services to all those with keen interest in different Chinese markets and industries. The firm, founded in 2007, is headquartered in Shanghai, China. Their team’s principle goal is to present the most helpful and reliable insights and information, sincerely serving a broad choice of multinational and local customers with their business practice and ethics.
CRI’s reports are packed with precise analysis of key market indicators, strategic recommendations from industry experts, market estimated figures, projections, reviews of competitive strategies, consumers investigation, reviews of business models, market share analyses, key forces driving of restraining market growth.
CRI’s scope of offerings encircles numerous market research reports, industry analytical reviews, company business reports, industry-specific research databases. Further, the company also offers outsource and custom-tailored services for research organisations, and multiple report readers.
Publications found:
1,334
Sort by:
Investigation Report on China's Goserelin Market 2021-2025
US$ 2,600.00
Goserelin is a synthetic analogue of a naturally occurring gonadotropin-releasing hormone (GnRH). Goserelin is developed by AstraZeneca, is mainly used to treat advanced breast and prostate cancer. In...
June 2021
50 pages
Investigation Report on China's Docetaxel Market 2021-2025
US$ 2,600.00
Docetaxel, sold under the brand name Taxotere, is a paclitaxel anti-tumor drug used for the treatment of locally advanced or metastatic non-small cell lung cancer. Docetaxel injection was first develo...
June 2021
50 pages
Investigation Report on China's Omalizumab Market 2021-2025
US$ 2,600.00
Omalizumab, developed by Novartis Europharm, is the only approved antibody designed to target and block immunoglobulin E (IgE). At the end of 2017, the FDA approved the registration of Novartis Europh...
June 2021
50 pages
Investigation Report on China's Pertuzumab Market 2021-2025
US$ 2,600.00
Pertuzumab is the first monoclonal antibody called 'HER dimerization inhibitor'. It mainly used to treat HER2-positive breast cancer. It was developed by Genentech, a subsidiary of Roche Pharma (Schwe...
June 2021
50 pages
Investigation Report on China's Dasatinib Market 2021-2025
US$ 2,600.00
Dasatinib, developed by Bristol-Myers Squibb, is an anti-tumor drug. It was first approved by the FDA in 2006 for the treatment of adult patients with Philadelphia chromosome-positive (Ph+) chronic my...
May 2021
50 pages
Investigation Report on China's Golimumab Market 2021-2025
US$ 2,600.00
Golimumab is an immunosuppressive medication that can effectively regulate inflammation and bone metabolism. The trade name of Golimumab is SIMPONI, which was developed by Janssen Biologics BV. Its pr...
May 2021
50 pages
Investigation Report on China's Propofol Market 2021-2025
US$ 2,600.00
Propofol is a short-acting intravenous anesthetic. Its uses include the induction and maintenance of general anesthesia, sedation for mechanically ventilated adults, and procedural sedation. It is als...
May 2021
50 pages
Investigation Report on China's Funeral Market 2021-2025
US$ 2,600.00
DESCRIPTION The funeral and interment industry can be divided into four parts from the perspective of service content: funeral services, disposal of remains, cemetery services, and other funeral produ...
May 2021
50 pages
Investigation Report on China's Ibrutinib Market 2021-2025
US$ 2,600.00
Ibrutinib is a BTK inhibitor, mainly used to treat B-cell carcinomas, such as mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenstrom's macroglobulinemia. Ibrutinib was first developed by...
April 2021
40 pages
Investigation Report on China's Iodixanol Market 2021-2025
US$ 2,600.00
Iodixanol is a third-generation contrast agent that has good solubility and is isotonic to plasma. It is used for cardiovascular angiography, cerebrovascular angiography, abdominal angiography, and so...
April 2021
50 pages
Investigation Report on China's Meropenem Market 2021-2025
US$ 2,600.00
Meropenem is an antibiotic that is used to treat a variety of bacterial infections, including meningitis, pneumonia and so on. Meropenem is jointly developed by Sumitomo Dainippon Pharma and Imperial...
April 2021
50 pages
Investigation Report on China's Nivolumab Market 2021-2025
US$ 2,600.00
Nivolumab is a human IgG4 monoclonal antibody that blocks PD-1, mainly used to treat non-small cell lung cancer, gastric or gastroesophageal junction adenocarcinoma, advanced renal cell carcinoma, and...
April 2021
50 pages
